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The  adaptive  immune  response  is  initiated 
through presentation of antigen to T cells by 
DCs. In the mouse, DCs can be broadly grouped 
into plasmacytoid DCs (pDCs) and conventional 
DCs  (cDCs;  earlier  termed  myeloid  DCs). 
Mouse cDCs can be further subdivided into 
several DC types, which are apparently special-
ized for optimal antigen uptake, processing, and 
presentation to T cells in different body compart-
ments (Steinman and Banchereau, 2007; Heath 
and Carbone, 2009; Segura and Villadangos, 
2009). One particular type of antigen presenta-
tion is cross-presentation: in this case, extracellular 
antigen is not classically presented in the con-
text of MHC-II but is instead shunted into the 
MHC-I presentation pathway (Bevan, 2006; 
Shen and Rock, 2006; Villadangos et al., 2007). 
CD8+ T cells can thus be activated by antigens 
taken up from the extracellular space and then 
differentiate into cytotoxic T cells. This mech-
anism is thought to be of major importance for 
the recognition of viral or bacterial antigens 
when DCs are not directly infected. In these 
instances, debris of cells that were infected 
and have subsequently undergone apoptosis 
as part of a cellular stress reaction is taken up and 
cross-presented by specialized DCs. Through 
this type of processing, the antigenic composi-
tion of the pathogen can become visible to the 
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In recent years, human dendritic cells (DCs) could be subdivided into CD304+ plasmacytoid 
DCs (pDCs) and conventional DCs (cDCs), the latter encompassing the CD1c+, CD16+, and 
CD141+ DC subsets. To date, the low frequency of these DCs in human blood has essentially 
prevented functional studies defining their specific contribution to antigen presentation. 
We have established a protocol for an effective isolation of pDC and cDC subsets to high 
purity. Using this approach, we show that CD141+ DCs are the only cells in human blood 
that express the chemokine receptor XCR1 and respond to the specific ligand XCL1 by Ca2+ 
mobilization and potent chemotaxis. More importantly, we demonstrate that CD141+ DCs 
excel in cross-presentation of soluble or cell-associated antigen to CD8+ T cells when 
directly compared with CD1c+ DCs, CD16+ DCs, and pDCs from the same donors. Both in 
their functional XCR1 expression and their effective processing and presentation of  
exogenous antigen in the context of major histocompatibility complex class I, human 
CD141+ DCs correspond to mouse CD8+ DCs, a subset known for superior antigen cross-
presentation in vivo. These data define CD141+ DCs as professional antigen cross-
presenting DCs in the human.
© 2010 Bachem et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it  is  available  under  a  Creative  Commons  License  (Attribution–Noncommer-
cial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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RESULTS
Strategy for identification and sorting of human cDC subsets
The highly restricted expression of XCR1 in subsets of mouse 
DCs was suggestive of a similarly restricted expression in the 
human. Therefore, we first established a reliable process for 
the identification and sorting of DC subsets from human 
blood. Although the phenotype of pDCs in human blood 
could be established unequivocally (Robinson et al., 1999; 
Dzionek et al., 2000), several differing approaches were un-
dertaken to define human cDCs in the past (Dzionek et al., 
2000; MacDonald et al., 2002; Lindstedt et al., 2005; Piccioli 
et al., 2007). Our strategy was based on the observation that 
all  human  blood  cDCs  express  HLA-DR  and  CD11c   
(MacDonald  et  al.,  2002),  and  on  the  conclusion  that 
HLA-DR+ CD34+ cells should not be regarded as DCs 
(Piccioli et al., 2007). Using the gating depicted in Fig. 1, we 
were able to clearly define distinct populations within cDCs, 
which in total represent 1.1% (±0.38% SD) of PBMCs in 
human blood (not depicted). The cDCs are composed of 
subsets  expressing  CD16  (68.2  ±  37.3%),  CD1c  (28.2  ± 
12.7%), and the very small subset expressing CD141 (3.6 ± 
2.7%). This gating strategy was the basis for the isolation of all 
cDC subsets to a very high purity.
The chemokine receptor XCR1 is selectively expressed  
in human CD141+ DCs
To identify cells expressing XCR1 in the human, we set up 
a highly sensitive and specific quantitative RT-PCR (qRT-
PCR), with forward and reverse primers in exons 1 and 3, 
respectively, and a probe in the noncoding region of exon 3 
(F1, R1, and P1; Fig. 2). This assay gave a very low signal 
with PBMCs (300 copies in 100 ng of total RNA; unpub-
lished data). To identify the source of this signal, we isolated 
CD8+ T cell immune system. In the mouse, extensive exper-
imentation has demonstrated that within cDCs, CD8+ DCs 
are the most effective in antigen cross-presentation (den Haan 
et al., 2000; Iyoda et al., 2002; Schulz and Reis e Sousa, 
2002; Heath et al., 2004). Whether mouse pDCs play a sig-
nificant role in antigen presentation and more so in antigen 
cross-presentation is controversial (Colonna et al., 2004; Liu, 
2005; Villadangos and Young, 2008).
We have recently shown in the mouse system that splenic 
CD8+ DCs (and their counterparts in other organs) are the 
only cells in the body expressing XCR1, a chemokine recep-
tor with a unique ligand, XCL1 (Dorner et al., 2009). In vitro, 
XCL1 induces potent chemotaxis of XCR1+ CD8+ DCs. 
In vivo, XCL1 secreted by activated CD8+ T cells augments 
their expansion and differentiation into cytotoxic T cells when 
the antigen is cross-presented by CD8+ DCs in the context of 
MHC-I (Dorner et al., 2009). Collectively, these observations 
indicate that the XCL1–XCR1 communication axis optimizes 
the cooperation of antigen-specific CD8+ T cells with XCR1+ 
DCs, which cross-present antigen to them.
Based on our studies in the mouse, we were interested to 
determine whether human DCs express XCR1. Human DCs 
have been extensively phenotyped in the past and subdivided 
again into pDC and into CD1c+ (BDCA-1+), CD16+, and 
CD141+  (BDCA-3+)  cDC  subsets  (Dzionek  et  al.,  2000; 
MacDonald et al., 2002; Piccioli et al., 2007; for review see Ju 
et al., 2010). Meticulous gene expression analyses of all human 
and mouse DCs have recently revealed a large gene expression 
program shared by human and mouse pDCs, and also led to 
the suggestion that human CD141+ DCs correspond to mouse 
CD8+ DCs (Robbins et al., 2008). In spite of this ground-
breaking work on the subdivision of human DCs into subsets, 
information on the function of human primary DCs remained 
very scarce, apparently because of the limitations imposed by 
the very low frequencies of DCs in human blood (CD1c+ 
DCs, 0.31 ± 0.14% SD; CD16+ DCs, 0.75 ± 0.41%; CD141+ 
DCs, 0.04 ± 0.03%; pDCs, 0.29 ± 0.08%; n = 8; not de-
picted). Instead, antigen cross-presentation in the human sys-
tem was essentially analyzed with DCs derived from monocytes 
in culture (Fonteneau et al., 2003), a system that may not re-
flect all of the functional properties of primary DCs.
In the present study, we demonstrate that CD141+ DCs 
are the only population in human blood that expresses the 
chemokine receptor XCR1. Human CD141+ DCs react to 
the chemokine XCL1 by mobilization of intracellular Ca2+ 
([Ca2+]i) and by strong chemotaxis in vitro. More impor-
tantly, our experiments demonstrate that primary CD141+ 
DCs  excel  in  cross-presentation  of  antigen  when  directly 
compared with CD1c+ DCs, CD16+ DCs, and pDCs from 
the same donors. Collectively, these functional data strongly 
indicate that human CD141+ DCs are the homologue of 
mouse CD8+ DCs. At the same time, the professional capac-
ity of human CD141+ DCs to cross-present antigen is of 
major interest in the ongoing quest to develop vaccines 
capable of inducing antiviral or antitumor cytotoxicity in 
the human.
Figure 1.  Strategy for defining human DC subsets in the blood. 
PBMCs from human blood were enriched by density gradient centrifuga-
tion and stained for the indicated cell-surface markers (for the mAb used 
for staining see Materials and methods). Flow sorting (after magnetic cell 
enrichment) was performed on the principle of the gating strategy shown. 
This approach allowed us to isolate CD304+ pDCs, CD16+ DCs, CD1c+ DCs, 
and CD141+ DCs to very high purities. The inset numbers represent the 
percentage of the gated cells in the respective gating step. FSC, forward 
scatter; SSC, side scatter.JEM VOL. 207, June 7, 2010 
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phosphoinositide  hydrolysis–dependent  and  inositol-1,4,5-
trisphosphate–triggered  mobilization  of  Ca2+  from  storage 
organelles. Approximately 20% of the cells responded only to 
the positive control (a mixture of CCL2, CCL21, CXCL9, 
and CX3CL1, selected based on the data of Robbins et al. 
[2008]), and 10% gave no response (Fig. 3). CD1c+ and 
CD16+ DCs, although alive and reactive, failed to respond to 
XCL1 under identical conditions (unpublished data). These 
results indicate that XCR1 is expressed on the cell surface in 
the majority of CD141+ DCs and can transduce an activation 
signal upon binding of its chemokine ligand, XCL1.
XCL1 selectively chemoattracts CD141+ DCs
To test human XCL1 for chemotaxis, highly purified, flow-
sorted DC subtypes were mixed at a ratio of 20% CD141+, 
40% CD16+, and 40% CD1c+ DCs (Fig. 4 A, Input DC) and 
assayed in a Transwell system. Without addition of a chemo-
kine, only CD16+ DCs within this mixed population exhib-
ited some background migration (Fig. 4 A). Upon addition 
of  increasing  amounts  of  XCL1,  a  selective  migration  of 
CD141+ DCs was observed (Fig. 4 A). At the optimal con-
centrations of XCL1 (100–1,000 ng/ml), >40% of all input 
CD141+ DCs migrated (in one experiment >70%). Checker-
board tests with XCL1 indicated true chemotaxis and not 
only chemokinesis (unpublished data). CD1c+ and CD16+ 
DCs responded to various concentrations of XCL1 only by 
background migration; positive controls with a mixture of 
the chemokines CCL2, CCL21, and CX3CL1 (Fig. 4 A, Mi-
grated DC) ensured that this unresponsiveness to XCL1 was 
not caused by a general unresponsiveness of these DC sub-
sets. In the literature, migration of T cells, B cells, NK cells, 
and  granulocytes  was  repeatedly  reported  in  response  to 
various cell types from PBMCs to a very high purity (see 
Materials and methods) and subjected them to qRT-PCR. 
No signal was obtained in T cells, B cells, NK cells, granulo-
cytes, monocytes, pDCs, CD1c+ DCs, and CD16+ DCs   
(Fig. 2 B). In contrast, a strong XCR1 signal (700,000 cop-
ies in 100 ng of total RNA) was obtained with CD141+ DCs 
(Fig. 2 B). In addition, we tested monocyte-derived DCs 
(MoDCs) in culture and found them to be negative (Fig. 2 B). 
To exclude cell-specific expression of a XCR1 splice variant, 
we used a primer set within the coding region of XCR1 for 
the qRT-PCR (F2, R2, and P2; Fig. 2 A) and obtained iden-
tical results (not depicted). In all assays, the 2-microglobulin 
signal was used as a positive control (unpublished data). Col-
lectively, these experiments determined that in human blood, 
XCR1 is only expressed in CD141+ DCs.
XCL1 mobilizes Ca2+ in CD141+ DCs but not in CD1c+  
and CD16+ DCs
To test the function of XCR1 in human CD141+ DCs, we 
isolated this subset as well as the other cDC subsets from 
human blood (purity in all instances was >98.7%) and ex-
posed them to XCL1. In a single-cell Ca2+ assay, 70% of all 
fura-2–loaded CD141+ DCs responded to XCL1 with a 
characteristic transient increase in [Ca2+]i indicative of a 
Figure 2.  The chemokine receptor XCR1 is selectively expressed in 
CD141+ DCs. (A) Organization of the human XCR1 gene (E1, exon 1; E2, 
exon 2; and E3, exon 3); the coding region is shown in black, and the 
primer–probe sets used for expression analyses are indicated. (B) qRT-PCR 
of total RNA from T cells, B cells, NK cells, granulocytes, monocytes, pDCs, 
CD1c+ DCs, CD16+ DCs, and CD141+ DCs isolated to a very high purity 
(>97.5%) from PBMCs and tested with primer–probe set 1 (F1, R1, and 
probe P1). Cultured MoDCs were also tested. Identical results were  
obtained using primer–probe set 2 (F2, R2, and P2; not depicted). The test 
systems used allowed the detection of ≥200 copies of XCR1 in cDNA  
reverse transcribed from 100 ng of total RNA. All PCR analyses were  
performed with cell subsets from at least two donors. Error bars represent 
means ± SEM.
Figure 3.  XCL1 induces a [Ca2+]i signal in CD141+ DCs. CD141+ DCs 
were flow sorted to a purity >98.7%, immobilized on poly–l-lysine–coated 
glass coverslips, and loaded with 2 µM fura-2/AM. Cells were imaged in a 
monochromator-assisted digital video imaging system and challenged 
with 1 µg/ml XCL1 as indicated (left arrow). Subsequently, the same cells 
were challenged again with a mixture of 100 ng/ml CCL2, 200 ng/ml 
CCL21, 200 ng/ml CXCL9, and 1 ng/ml CX3CL1 used as a positive control 
(right arrow). The data shown represent [Ca2+]i concentrations of  
300 single cells (gray lines) measured in two independent experiments.  
The mean [Ca2+]i signal averaged over all cells responding to XCL1 is  
indicated (black line).1276 Human CD141+ DCs correspond to mouse CD8+ DCs | Bachem et al.
(Dorner et al., 2009). We therefore 
decided  to  directly  compare  human 
CD141+ DCs with the other DC sub-
types for antigen cross-presentation 
when purified from the blood of single 
donors. To this end, CD141+ DCs, 
CD1c+ DCs, CD16+ DCs, and pDCs 
from HLA-A*0201 donors were co-
cultured with a CD8+ T cell clone 
recognizing the human CMV (HCMV) 
peptide  NLVPMVATV  (pp65495–503) 
when  presented  in  the  context  of 
HLA-A*0201. Addition of recombi-
nant  pp65  protein  in  a  soluble  form  to  co-cultures  with 
CD141+ DCs triggered strong IFN- secretion by the T cell 
clone, indicating an efficient intracellular degradation of pp65 
and subsequent presentation of the NLVPMVATV peptide 
on the surface of this DC subset (Fig. 5 A). Addition of 
recombinant  pp65  protein  to  co-cultures  with  CD1c+  or 
CD16+ DCs resulted in clearly lower IFN- signals; in the 
case of pDCs the signal was minimal (Fig. 5 A). Addition 
of OVA, a protein whose degradation products cannot be 
recognized by the T cell clone, gave only minimal background 
signals, as was the case in cultures containing only T cells or 
DCs (Fig. 5 A). Positive controls with the pp65 peptide 
XCL1 (for a compilation of references see Dorner et al., 
2009).  When  we  performed  analogous  Transwell  experi-
ments, XCL1 failed to induce migration with any of these 
cell populations, whereas the respective positive control 
chemokines (CXCL12 and CXCL8) were effective (Fig. 4 C). 
Collectively, these experiments established that XCL1 is a 
chemokine with selective action on CD141+ DCs.
CD141+ DCs efficiently cross-present antigen
In the mouse system, XCR1 is exclusively expressed on a 
DC subset (bearing the surface marker CD8 in the spleen) 
known for its superior capacity to cross-present antigen in vivo 
Figure 4.  XCL1 selectively induces che-
motaxis in CD141+ DCs. (A) A mixture of 
highly purified, flow-sorted DC subtypes (20% 
CD141+, 40% CD16+, and 40% CD1c+ DCs; 
Input DC) was tested for migration in  
response to medium alone or to serial dilu-
tions of XCL1 (10–5,000 ng/ml) in a Transwell 
system. A combination of the chemokines 
CCL2, CCL21, and CX3CL1 was used as a posi-
tive control for the DC subsets (Migrated DC). 
The absolute numbers of CD141+, CD1c+, and 
CD16+ DCs in input and migrated cell popula-
tions are truly represented in the dot plots, 
because all cells within a defined volume were 
included in the analysis in each instance.  
(B) Proportion of migrated CD1c+, CD16+, and 
CD141+ DCs in the experiment shown in A.  
(C) Proportion of migrated pDCs, monocytes, 
granulocytes, T cells, B cells, and NK cells in 
response to XCL1 (10–1,000 ng/ml) or the 
chemokines CXCL12 and CXCL8, which were 
used as positive controls. For migration assays 
of B cells, NK cells, and monocytes, PBMCs 
were magnetically depleted of T cells, and for 
T cell migration, PBMCs were used directly. 
For migration assays of granulocytes, whole 
blood cells were used after erythrocyte lysis 
with ACK buffer, and pDCs were magnetically 
enriched from PBMCs with the Plasmacytoid 
Dendritic Cell Isolation Kit (Miltenyi Biotec). 
All experiments with DCs were performed 
three times; all other populations were assayed 
twice. Error bars represent means ± SEM.JEM VOL. 207, June 7, 2010 
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DC subsets, a recent study substantiated these suggestions 
(Robbins et al., 2008). In our current work, we now demon-
strate that CD141+ DCs, which represent only 3–4% of all 
DCs in human blood, exclusively express the chemokine re-
ceptor XCR1 and selectively respond to the chemokine li-
gand XCL1 by [Ca2+]i mobilization and chemotaxis. More 
importantly in terms of biological function, we now show 
that CD141+ DCs excel in cross-presentation of antigen to 
CD8+ T cells when directly compared with all other human 
NLVPMVATV present in the co-cultures (containing lower 
numbers of T cells and DCs) gave a comparably strong IFN- 
signal with all cDC subsets but a lower signal with pDCs 
(Fig. 5 A), although the viability of all DC subtypes at the end 
of the co-culture period was in the range of 60–70%.
Because  cross-presentation  is  mainly  implicated  in  the 
uptake of cell debris, we also performed analogous tests with 
the cell-associated HCMV pp65 protein. CD141+, CD1c+, 
or CD16+ DCs were co-cultured with a CD8+ T cell clone 
at variable ratios of 1:1 to 1:16 in the presence of cell material 
obtained by repeated freeze–thaw cycles of a HCMV pp65 
transfectant. These cross-presentation tests gave strong IFN- 
signals with CD141+ DCs, and only low responses with 
CD1c+ and CD16+ DCs (Fig. 5 B). The signals obtained 
with the negative control peptide MART-127–35 were always 
minimal with CD141+ and CD1c+ DCs; the positive con-
trols with the pp65495–503 peptide indicated similar expression 
of HLA-A*0201 on the surface of these cDC subsets. Col-
lectively, these tests with soluble or cell-associated HCMV 
pp65 demonstrated a superior capacity of CD141+ DCs to 
cross-present antigen to CD8+ T cells.
DISCUSSION
The very low frequencies of pDCs and cDCs in human blood 
strongly impeded functional studies with primary populations 
in the past. As a result, data on antigen presentation, and in 
particular  on  antigen  cross-presentation,  remained  scarce. 
This  limited  information  also  made  it  difficult  to  directly 
compare human cDC subsets with the extensively character-
ized mouse cDC subtypes. In the mouse, it has been recog-
nized  that  each  DC  subset  is  optimally  equipped  for  the 
uptake, recognition, and presentation of different antigens or 
pathogens. One particular mouse cDC subset bearing the 
CD8 marker in the spleen (CD8+ DCs) very efficiently takes 
up antigen from the extracellular space and cross-presents it 
to CD8+ T cells (den Haan et al., 2000; Iyoda et al., 2002; 
Schulz and Reis e Sousa, 2002; Heath et al., 2004). This pro-
fessional antigen cross-presentation is regarded as important 
for the immune defense of intracellular viral and bacterial 
pathogens, as well as for the eradication of tumor tissue (Lin 
et al., 2008; Shortman and Heath 2010). We have recently 
shown that these mouse splenic CD8+ DCs (and their coun-
terparts in other organs) exclusively express the chemokine 
receptor XCR1 and selectively migrate to its chemokine 
ligand XCL1 (Dorner et al., 2009).
We now have developed an effective scheme for the iso-
lation of all currently defined human DC subsets, including 
pDCs (CD304+) and cDCs (CD1c+, CD16+, or CD141+) to 
a very high purity from single-blood donations. This approach 
allowed us to search for the human counterpart of the cross-
presenting mouse CD8+ DCs. In the past, concordant ex-
pression  of  certain  cell-surface  molecules  on  both  human 
CD141+ DCs and mouse CD8+ DCs led to initial suggestions 
that these two DC subsets may be related (Galibert et al., 
2005; Caminschi et al., 2008). By meticulously comparing 
the gene expression patterns of all known human and mouse 
Figure 5.  Capacity of CD141+, CD1c+, and CD16+ DCs to cross-
present soluble and cell-associated HCMV pp65 antigen. (A) CD8+  
T cell clone 10, specific for the HLA-A*0201–restricted HCMV pp65 peptide 
NLVPMVATV (pp65495–503), was co-cultured with CD141+ DCs, CD1c+ DCs, 
CD16+ DCs, or pDCs obtained from the buffy coat of one HLA-A*0201+ 
blood donation, with 3 µg/ml of recombinant soluble HCMV pp65 added 
for the entire culture period. The activation of the T cell clone was deter-
mined by measuring the concentration of IFN- in the supernatants at 
the termination of culture after 20 h. Negative controls included addition 
of irrelevant protein OVA (3 µg/ml) and cultures with only the T cell clone 
or DCs; addition of 1 µg/ml of pp65495–503 peptide to the co-cultures 
served as a positive control. Shown is one representative experiment out 
of nine; each experiment was performed with cells from a different donor 
(all experiments included all cDCs subsets; four of them also included 
pDCs). (B) CD141+, CD1c+, or CD16+ DCs isolated from leukapheresis 
PBMCs of one HLA-A*0201+ donor were co-cultured with CD8+ T cell 
clone 61 at variable ratios (from 1:1 to 1:16) with cell-associated pp65 
antigen added for the entire culture period, and IFN- was determined in 
the supernatant after 24 h. Negative controls included irrelevant  
MART-127–35 peptide, and positive controls included HCMV pp65495–503 
peptide (both at 1 µg/ml). Shown are results representative of three  
experiments with different donors. Error bars represent means ± SEM.1278 Human CD141+ DCs correspond to mouse CD8+ DCs | Bachem et al.
for XCR1, is coexpressed with IFN- by NK cells and CD8+ 
T cells upon activation in vitro (Dorner et al., 2002). Further, 
in the mouse Listeria infection model, XCL1 was secreted by 
NK cells in the early phase of the infection and by antigen-
experienced CD8+ T cells in the recall response (in each in-
stance together with IFN-). These observations led to the 
concept of XCL1 and IFN- acting (together with other cy-
tokines) as a functional cytokine unit in the defense of certain 
infections (Dorner et al., 2002). With the recognition of cross-
presenting DCs as the only cells bearing XCR1, this concept 
can be further refined. Thus, in the early innate response, 
XCL1 may ensure contact and thus exchange of information 
between activated NK cells and XCR1-bearing DCs. Later, 
in the adaptive phase and on reexposure, this cytokine func-
tional unit is handed over to CD8+ T cells and thus ensures 
proper communication between cross-presenting DCs and 
CD8+ T cells (Fig. 6), as also demonstrated experimentally 
(Dorner et al., 2009). The XCL1–XCR1 communication 
axis thus apparently optimizes the differentiation and func-
tion of innate and adaptive cytotoxic cells required for an ef-
fective response against certain (intracellular?) pathogens.
Finally, the identification of human professional cross-
presenting DCs provides new avenues for the development 
of antiviral and antitumor vaccines based on the induction of 
cytotoxic T cells (Steinman and Banchereau, 2007; Andrews 
et al., 2008; Caminschi et al., 2009). The involvement of the 
pDC and cDC subsets in vitro. Collectively, these results 
define CD141+ DCs as professional antigen–cross-presenting 
DCs in the human and allow the conclusion that this DC 
subset is the homologue of mouse CD8+ DCs.
The identification of professional human cross-presenting 
DCs is an important step forward, because it indicates that 
the biological concepts on antigen cross-presentation derived 
from extensive experimentation in the mouse can appar-
ently be transferred to the human. However, many questions 
remain to be answered. For example, the identification of 
cross-presenting DCs in the blood raises the issue of whether 
these cells are also resident in lymphoid tissues and other 
organs. Our preliminary data clearly point in this direction. 
In the thymus, we could observe that CD141+ cDCs express 
XCR1 mRNA, and CD141+ cells obtained from tonsillecto-
mies also gave substantial PCR signals for XCR1. Attempts 
to  locate  human  CD141+  DCs  in  lymphoid  tissues  using 
histology were confounded by a relatively diffuse expression 
pattern obtained in areas populated by lymphoid cells and 
by the dominant expression of CD141 on the endothelium 
(Esmon et al., 1982). A definitive proof of the presence of 
human DCs capable of antigen cross-presentation in lym-
phoid tissues will require further phenotypic dissection of 
the local DC subtypes combined with antigen presentation 
studies in vitro.
We are not aware of any data in the literature on the ca-
pacity of CD141+ DCs to present or cross-present antigen to 
T cells. With other primary human DC subsets, functional 
data  on  cross-presentation  are  very  scarce.  Schnurr  et  al. 
(2005) functionally compared primary CD1c+ DCs (cultured 
overnight with GM-CSF) with primary pDCs (cultured with 
IL-3) and found only CD1c+ DCs capable of antigen cross-
presentation to CD8+ T cells, whereas pDCs were totally 
ineffective. In contrast, Hoeffel et al. (2007) reported a simi-
lar cross-presentation by cDCs and pDCs, and Di Pucchio 
et al. (2008) also found a comparable cross-presentation 
capacity of CD1c+ DCs and pDCs. In neither of the cited 
reports have CD141+ DCs been removed before experimen-
tation, but this technical aspect is unlikely to be the cause for 
the differing results, because the frequency of CD141+ DCs 
within the tested DC populations is so low. Instead, other 
technical details may have influenced the results. Hoeffel 
et al. (2007), e.g., have used a lipopeptide as a source of antigen 
(for a short-term assay), whereas Di Pucchio et al. (2008) as-
sessed antigen cross-presentation by quantifying CD8+ T cell 
proliferation over 6 d. In our experiments, CD141+ DCs 
were clearly superior to CD1c+ and CD16+ DCs in their ca-
pacity to cross-present soluble or cell-associated antigen to 
CD8+ T cells in a short-term, highly quantitative assay system 
in which survival of all tested DC subpopulations was similar. 
In the same setup, pDCs were consistently ineffective.
The tight correlation between the expression (and func-
tion) of the chemokine receptor XCR1 and the capacity of 
DCs to cross-present antigen in the mouse and in the human 
is suggestive of a biological linkage. We have previously 
demonstrated that XCL1, the only known chemokine ligand 
Figure 6.  Involvement of the XCL1–XCR1 communication axis in 
the innate and adaptive cytotoxic responses to cross-presented 
microbial and tumor antigens. Secretion of the chemokine XCL1 by 
activated NK cells specifically attracts XCR1-expressing DCs capable of 
antigen cross-presentation. This ensures an effective communication 
between these cells in the innate phase of the immune response. In the 
adaptive phase, secretion of XCL1 by activated CD8+ T cells optimizes the 
communication with antigen cross-presenting DCs and facilitates the 
differentiation of CD8+ T cells to cytotoxic cells.JEM VOL. 207, June 7, 2010 
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standards for mRNA/cDNA copy quantitation, the specific XCR1 gene 
fragments were amplified and cloned into pJET1.2 vectors using the Clone-
JET PCR cloning kit (Fermentas). For quantitative PCR, primers were 
mixed with 10 µl ABsolute QPCR Mix including ROX (ABgene) and 1/10 
of the cDNA in a 20-µl PCR reaction. PCR was performed and quantified 
on a 7500 Fast Real-Time PCR System (Applied Biosystems) with initial 
enzyme activation at 95°C for 15 min, followed by 40 cycles (95°C for 15 s 
and 60°C for 1 min).
Fluorometric [Ca2+]i determination. CD141+, CD1c+, and CD16+ DCs 
were freshly flow sorted to a purity >98.7%, as described in Cell isolation for 
RNA preparation... The sorted cell suspensions were washed (200 g for 5 min) 
and resuspended in Hepes-buffered solution (HBS) containing 128 mM NaCl, 
6 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 5.5 mM glucose, 10 mM Hepes, 
and 0.2% BSA, supplemented with 2 µM fura-2/AM (Invitrogen). Cell sus-
pensions were allowed to settle and adhere on poly–l-lysine–coated glass 
coverslips at 37°C and 5% CO2 for 30 min in a humidified atmosphere. 
Coverslips were superfused with HBS, mounted in a bath chamber, and 
imaged with an inverted microscope (Axiovert 100; Carl Zeiss, Inc.) using a 
UV-transmissive 10×/0.5 Fluar objective. During and after application of 
1,000 ng/ml XCL1 or a chemokine mix (100 ng/ml CCL2, 200 ng/ml 
CCL21, 200 ng/ml CXCL9, 1 ng/ml CX3CL1) as a positive control, the 
fura-2/AM fluorescence was sequentially excited with monochromatic 
light of 340, 358, and 380 nm, and fluorescence emission was detected 
through a 512-nm-long pass filter with a cooled charge-coupled device camera 
(TILL-Photonics). Signals arising from the bound and unbound Ca2+ indica-
tor were averaged over regions of interest that covered the area of single 
immobilized cells. Spectrally overlapping signals were separated and [Ca2+]i 
was calculated by a spectral fingerprinting method (Lenz et al., 2002). To assess 
a  possible  impact  of  contaminating  fluorescence  arising  from  fluoro-
chrome-labeled antibodies, cell suspensions were treated and imaged in a 
similar way but without fura-2/AM loading. Under these conditions, 
there were no fluorescence signals discernible when excited at 340, 358, 
or 380 nm; we thus conclude that the fluorescence signals required no 
additional preprocessing.
Chemotaxis assay. For chemotaxis assays, 105 cells suspended in 100 µl of 
medium (RPMI 1640, 1% BSA, 50 µM -ME, 100 µg/ml penicillin/
streptomycin) were placed into the upper chamber of a Transwell-24 system 
(6.5-mm diameter, 5-µm pore polycarbonate membrane; Costar; Corning). 
The lower chamber was filled with chemotaxis medium containing recom-
binant human XCL1 (R&D Systems) or any of the chemokines CCL2 
(100 ng/ml), CCL21 (200 ng/ml), CX3CL1 (1 ng/ml), CXCL12 (200 ng/ml 
for T cells, B cells, NK cells, and monocytes; 100 ng/ml for pDCs), and 
CXCL8 (100 ng/ml; all from R&D Systems), and the cells were incubated 
for 150 min at 37°C in 5% CO2. In the lower chamber, cDCs (CD141+, 
CD1c+, CD16+), pDCs (CD304+, HLA-DR+, CD11c, CD3, CD14, 
CD19, CD56), T cells (CD3+, CD19, CD14), B cells (CD19+, CD3, 
CD14), NK cells (CD56+, CD16+, CD3, CD14, CD19), monocytes 
(CD14+,  CD3,  CD19),  and  granulocytes  (CD15+,  CD45+,  CD14, 
CD19) were identified by the indicated markers using flow cytometry. The 
absolute number of input or migrated cells was determined by counting all 
cells in a defined volume with a flow cytometer, and the percentage of mi-
grated cells was calculated by dividing the number of cells in the lower 
chamber by the number of input cells (number of migrated cells/number of 
input cells × 100). All experiments were performed with duplicate wells.
HCMV pp65495–503–specific CD8+ T cell clone. An HLA-A*0201–
restricted, HCMV pp65–specific CD8+ T cell clone was prepared accord-
ing to the procedure of Fonteneau et al. (2001). In brief, T cells from an 
HLA-A*0201+ donor were stimulated with autologous mature MoDCs, 
which were pulsed with pp65495–503. The activated T cells were expanded 
and cloned by limiting dilution; two of the pp65-specific CD8+ T cell 
clones (clones 10 and 61) were further expanded on irradiated feeder cells (an 
EBV line [2 × 104 cells/well] and PBMCs [2 × 105 cells/well], both irradiated 
XCL1–XCR1 communication axis in the innate and adap-
tive cytotoxic responses against certain infections (and possi-
bly also tumors) makes XCR1 an interesting target for the 
delivery of prophylactic or therapeutic vaccines to cross-
presenting DCs. The selectivity of XCR1 expression on these 
DCs, unmatched by any other known cell-surface molecule, 
and the typical internalization of chemokine receptors upon 
ligand binding further make this targeting route attractive.
MATERIALS AND METHODS
Antibodies and flow cytometry. Antibodies recognizing CD19 (clone 
BU12; Flavell et al., 1995), CD3 (OKT3), CD14 (63D3), HLA-DR 
(L243; all from American Type Culture Collection), CD11c (BU15), 
CD15 (W6D3), CD16 (3G8), CD45 (HI30), CD56 (HCD56), HLA-A2 
(BB7.2;  BioLegend),  CD1c  (AD5-8E7),  CD141  (AD5-14H12),  and 
CD304 (AD5-17F6; Miltenyi Biotec) were used. Data were acquired on a 
flow cytometer (LSR II; BD) and analyzed using FlowJo software (Tree 
Star, Inc.).
Cell isolation for RNA preparation, fluorometric [Ca2+]i determi-
nation, and cross-presentation assays. PBMCs were prepared by stan-
dard  Biocoll  (Biochrom)  density  gradient  centrifugation  of  buffy  coats 
from preoperative autologous deposits or of peripheral blood cells obtained 
from volunteers by leukapheresis. Leukapheresis was based on written in-
formed consent and was approved by the local ethics committee. For prep-
aration of granulocytes, whole blood was subjected to erythrocyte lysis 
with ACK buffer (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) 
followed  by  flow  sorting  (CD45+,  CD15+,  CD3,  CD14,  CD19, 
CD141) to a purity >99.7%. T cells (CD3+, CD19, CD141), B cells 
(CD19+, HLA-DR+, CD3, CD141), NK cells (CD16+, CD56+, CD3, 
CD141, HLA-DR), and monocytes (CD14+, CD3, CD19, CD141) 
were flow sorted from PBMCs to a purity >99.4%. CD1c+ DCs (CD1c+, 
CD11c+, HLA-DR+, CD16, CD141, lin; ≥99.5% pure), CD16+ DCs 
(CD16+,  CD11c+,  HLA-DR+,  CD1c,  CD141,  lin;  ≥99.2%  pure), 
CD141+  DCs  (CD141+,  CD11c+,  HLA-DR+,  CD1c+,  CD16,  lin; 
≥97.5% pure), and pDCs (CD304+, HLA-DR+, CD11c, CD141, lin; 
≥99.9% pure) were flow sorted from PBMCs after magnetic enrichment 
with the respective cell isolation kits from Miltenyi Biotec. In all flow sort-
ing experiments, cells were preincubated with 2 mg/ml Endobulin (Baxter 
Hyland-Immuno Division) for 5 min at 4°C to block unspecific binding of 
mAbs. Flow sorting of cells was performed on a cell sorter (FACSAria II; 
BD). For generation of MoDCs, monocytes were enriched from PBMCs 
with CD14 microbeads and cultured for 5 d in RPMI 1640 medium sup-
plemented with 10% FCS, penicillin, streptomycin, 500 U/ml GM-CSF, 
and 100 U/ml IL-4.
PCR. Total RNA was prepared using the High Pure RNA Isolation Kit 
(Roche). RNA concentration, purity, and integrity were determined on 
a  2100  Bioanalyzer  (Agilent  Technologies)  and  by  photometrical  read-
ing on a NanoDrop 1000 (Thermo Fisher Scientific). For determination 
of XCR1 expression, 100 ng of total RNA were reverse transcribed 
into cDNA with hexamer primers and the AMV Reverse Transcrip-
tion System (Promega), and analyzed by quantitative PCR using the fol-
lowing primer–probe sets: 5-TCAAGACGCATGTAAAGAGGTGTAG-3 
(forward  primer  F1),  5-GTTGCCTGAGGACTCCATCTG-3  (reverse 
primer  R1),  and  5-FAM-TGCTCTAAACGTCCCTGCCATCTGGT-
TAMRA-3 (probe P1); and 5-TTGCCTGTGTGGATCTCCC-3 (for-
ward primer F2), 5-CGGTGGATGGTCATGATGG-3 (reverse primer 
R2),  and  5-FAM-CATCAGCCTCTACAGCAGCATCTTCTTCCT-
TAMRA-3 (probe P2). Amplification of 2-microglobulin was used 
as a positive control: 5-GCCGTGTGAACCATGTGACT-3 (forward),   
5-CGGCATCTTCAAACCTCCA-3 (reverse), and 5-FAM-TAAGTGG-
GATCGAGACATGTAAGCAGCATC-TAMRA-3 (probe). To generate 1280 Human CD141+ DCs correspond to mouse CD8+ DCs | Bachem et al.
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with 43 Gy) using 1 µg/ml leucoagglutinin PHA-L (Sigma-Aldrich) and 
150 U/ml of recombinant IL-2. Before being used in an assay, the T cell 
clones were rested for at least 10 d.
Cross-presentation assay. Soluble recombinant HCMV pp65 (low endo-
toxin) was obtained from Miltenyi Biotec. Recombinant OVA (Sigma-Aldrich), 
from which LPS was removed using EndoTrap red (Hyglos), resulting in 
<0.5 U of endotoxin per milligram of protein as determined by the LAL assay 
(Charles River), was taken up in the same buffer as recombinant pp65. For cell-
associated  pp65  antigen,  full-length  HCMV  pp65  cDNA  cloned  into  the 
pcDNA3.1/myc-His vector (24 µg) was mixed with 24 µl Lipofectamine 2000 
in 3 ml of Opti-MEM medium (all from Invitrogen) and used to transfect 
2 × 106 HeLa cells (American Type Culture Collection) overnight according to 
the manufacturer’s instructions. Transfected HeLa cells were trypsinized, ad-
justed to 2 × 106 cells/ml in RPMI 1640 containing 10% FCS, and subjected to 
four freeze–thaw cycles. Transfection efficiency was monitored by Western 
blotting of 5 µg of protein lysate (determined with a BCA Protein Assay; Thermo 
Fisher Scientific) using HCMV pp65 mAb (CH12; Santa Cruz Biotechnology, 
Inc.). Cross-presentation of pp65 antigens by DCs was examined as described 
previously (Fonteneau et al., 2003). In brief, highly purified DC subtypes were 
co-cultured with a T cell clone in round-bottom 96-well plates in RPMI 1640, 
10% FCS (Biochrom), penicillin, and streptomycin in the presence of antigen for 
20–24 h. In cultures with recombinant soluble pp65 or OVA proteins (each at 
3 µg/ml), T cell clone 10 was co-cultured with DCs (both at 4 × 104 cells/well) 
in 100 µl of complete medium; for the positive control with pp65495–503 peptide 
(1 µg/ml), T cell clone 10 and DCs (both at 104 cells/well) were co-cultured 
in 30 µl of medium. In cultures with cell-associated pp65, T cell clone 61 
(5 × 104 cells/well) was co-cultured at variable ratios with DC subsets in a final 
volume of 150 µl of complete medium in the presence of HeLa pp65 lysate 
(50  µl)  or  MART-127–35  peptide  AAGIGILTV  or  pp65495–503  peptide 
NLVPMVATV (both synthesized in our own facility and used at 1 µg/ml). In 
all instances, stimulation of the T cell clone was determined by quantifying the 
amount of IFN- secreted into the supernatant. ELISA for IFN- was per-
formed according to the manufacturer’s instructions (OptEIA Human IFN- 
ELISA Set; BD), optical density was determined at 450 nm, and the data were 
evaluated with Revelation software (version 4.21; Dynex Technologies).
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